Rocket Pharmaceuticals Inc (NASDAQ:RCKT) Expected to Post Earnings of -$0.52 Per Share

Brokerages predict that Rocket Pharmaceuticals Inc (NASDAQ:RCKT) will announce earnings of ($0.52) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Rocket Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.69) and the highest estimate coming in at ($0.40). Rocket Pharmaceuticals posted earnings per share of ($0.66) in the same quarter last year, which would indicate a positive year-over-year growth rate of 21.2%. The company is expected to issue its next earnings results on Thursday, March 5th.

According to Zacks, analysts expect that Rocket Pharmaceuticals will report full year earnings of ($1.68) per share for the current financial year, with EPS estimates ranging from ($1.89) to ($1.54). For the next financial year, analysts anticipate that the company will report earnings of ($2.28) per share, with EPS estimates ranging from ($3.45) to ($1.57). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Rocket Pharmaceuticals.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.11.

A number of equities research analysts have recently commented on the company. Zacks Investment Research downgraded Rocket Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 26th. William Blair reiterated a “buy” rating on shares of Rocket Pharmaceuticals in a research report on Tuesday, September 10th. Chardan Capital reissued a “buy” rating and issued a $30.00 price target on shares of Rocket Pharmaceuticals in a research note on Friday. Robert W. Baird lifted their price target on Rocket Pharmaceuticals from $30.00 to $41.00 and gave the company an “outperform” rating in a report on Friday. Finally, Cowen reaffirmed a “buy” rating on shares of Rocket Pharmaceuticals in a research note on Sunday, November 17th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $31.50.

Rocket Pharmaceuticals stock traded up $2.65 on Friday, hitting $22.37. The company’s stock had a trading volume of 1,002,018 shares, compared to its average volume of 242,551. Rocket Pharmaceuticals has a one year low of $10.75 and a one year high of $24.42. The firm has a market cap of $992.91 million, a P/E ratio of -11.83 and a beta of 2.78. The company has a quick ratio of 11.07, a current ratio of 11.07 and a debt-to-equity ratio of 0.20. The company has a fifty day moving average price of $15.56 and a 200-day moving average price of $13.98.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Lindbrook Capital LLC raised its stake in shares of Rocket Pharmaceuticals by 200.0% in the 3rd quarter. Lindbrook Capital LLC now owns 3,000 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 2,000 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its holdings in Rocket Pharmaceuticals by 41.5% during the third quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 8,150 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 2,390 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Rocket Pharmaceuticals by 41.7% during the second quarter. JPMorgan Chase & Co. now owns 8,168 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 2,404 shares in the last quarter. Bank of Montreal Can acquired a new stake in Rocket Pharmaceuticals in the second quarter worth approximately $38,000. Finally, Northern Trust Corp lifted its position in Rocket Pharmaceuticals by 0.9% in the second quarter. Northern Trust Corp now owns 308,274 shares of the biotechnology company’s stock worth $4,624,000 after purchasing an additional 2,784 shares during the period. Institutional investors own 93.86% of the company’s stock.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.

Read More: What is the Shanghai Stock Exchange Composite Index?

Get a free copy of the Zacks research report on Rocket Pharmaceuticals (RCKT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Rocket Pharmaceuticals (NASDAQ:RCKT)

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.